Last reviewed · How we verify
0.005% calcipotriol
At a glance
| Generic name | 0.005% calcipotriol |
|---|---|
| Also known as | Daivonex solution 0.005% |
| Sponsor | ISDIN |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Rash erythematous
- Dermatitis contact
- Skin erosion
- Pain in extremity
- Erythema
- Scab
- Lividity
- Skin haemorrhage
Key clinical trials
- Comparison of Topical Photodynamic Therapy With Topical Calcipotriol in Management of Oral Leukoplakia (PHASE3)
- Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata (PHASE4)
- Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis. (PHASE2)
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (NA)
- COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO (EARLY_PHASE1)
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC (PHASE1)
- A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |